As the second most common malignant tumor in the female reproductive system in China, cervical cancer has long been a lingering burden on women’s health. However, the human papillomavirus (HPV) vaccine, which can prevent cervical cancer, has been delayed in the market in China. What is the current knowledge of HPV vaccine among medical professionals in China? Would they recommend it to patients? A total of 4608 medical professionals expressed their views on HPV vaccine in a 1-month survey conducted by the Clove Survey. According to the results of a survey conducted in 2015 among the general medical checkup population, the HPV vaccine awareness rate was only 26%. The overall awareness rate of doctors in this survey was 78%, with oncology and obstetrics and gynecology performing the best. In addition to reading professional literature, another very important thing for medical professionals to do is to go online. According to the China Physician Digital Life Report 2015, physicians spent an average of 24.2 hours per week on the Internet in 2015, more than half of which were related to their specialty. It’s no surprise, then, that learning about the HPV vaccine is done online. 70% of medical professionals believe both men and women should be vaccinated Based on the available clinical trial evidence, the HPV vaccine is effective in preventing not only cervical cancer, but also anal cancer, genital warts and other diseases, so 72% of respondents in the survey believe both men and women should be vaccinated against HPV. However, in the WHO HPV vaccination promotion document released in 2014, it was stated that male HPV vaccination is not recommended as a priority, taking into account the economic benefits of different regions. Hong Kong is the first choice for HPV vaccination in mainland China The HPV vaccine is now available in most countries/regions around the world, with more than 80 countries/regions having included it in their national vaccination promotion programs and 30 countries/regions having included it in their pilot vaccination programs. In recent years, HPV vaccine has become a popular health travel product as travel and health needs collide. Hong Kong has become the best choice for HPV vaccination for mainlanders, with 67% of vaccinated medical professionals receiving the vaccine in Hong Kong and 84% of those planning to receive the vaccine in Hong Kong. The convenience of traveling to Hong Kong, the favorable price of the vaccine, and the lack of communication barriers have all contributed to the popularity of HPV vaccination in Hong Kong, with 87% of doctors reporting that their relatives and friends are getting their HPV vaccination in Hong Kong. What are medical professionals who don’t want to get vaccinated worried about? If the HPV vaccine is released in China in the future, only 28% of medical professionals will receive the vaccine (regardless of age and gender), while the remaining 68% of medical professionals are still in a wait-and-see / hesitant state. Among them, “fear of vaccine side effects” is the main factor that prevents them from looking forward to vaccination. What are the concerns of those who do not recommend vaccination? When it came to family and friends, the responses were very different: Nearly 62% of health professionals said they would recommend the HPV vaccine to family and friends. Those who would not recommend it preferred to leave the decision up to family and friends, and side effects were also a concern. When dealing with patients, the highest percentage of health professionals would recommend the HPV vaccine to patients inquiring about it. Those who did not recommend the vaccine did so primarily because of their own job responsibilities and scope. As with the above concerns, if the HPV vaccine is available in China, safety is the primary factor that determines the medical staff’s consideration, followed by vaccine effectiveness, price, and manufacturer. The medical staff does not care much about the price type of the vaccine. Although price is not the main factor for medical professionals to consider vaccination, the high price still discourages many people. Currently, three doses of HPV vaccine in the United States and Hong Kong costs about $2,500 in RMB. The survey shows that most medical professionals can accept a price of less than $1,000. When asked if the vaccine could be promoted to the target population, 75% of the medical staff said they would support it. Among those who were neutral or opposed, the main concern was the safety and efficacy of the vaccine.